PATH vs RLYB · P/E 19, rev $1.61B vs rev $212.0K
Uipath Inc (PATH) versus Rallybio Corp (RLYB) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Rallybio Corp (RLYB) is a biotechnology company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported RLYB revenue for 2025-09-30 was $212.0K. Net income was $16.0M. Revenue was up 0.0% from 2025-06-30 to 2025-09-30. RLYB currently screens at market cap $13.8M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. RLYB currently screens at market cap $13.8M.
Not investment advice. Open the PATH and RLYB stock pages for the full models.
Not investment advice.